DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) has received an average recommendation of “Moderate Buy” from the six research firms that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $12.3333.

A number of analysts recently issued reports on the company. Wall Street Zen cut DiaMedica Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. Lake Street Capital reiterated a “buy” rating on shares of DiaMedica Therapeutics in a report on Monday, January 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research note on Wednesday, January 21st. Finally, Cantor Fitzgerald started coverage on shares of DiaMedica Therapeutics in a research report on Friday, November 14th. They set an “overweight” rating on the stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Invesco Ltd. lifted its stake in shares of DiaMedica Therapeutics by 29.9% in the 4th quarter. Invesco Ltd. now owns 18,628 shares of the company’s stock valued at $148,000 after purchasing an additional 4,293 shares during the last quarter. XTX Topco Ltd bought a new position in DiaMedica Therapeutics during the fourth quarter valued at about $234,000. Wellington Management Group LLP acquired a new stake in shares of DiaMedica Therapeutics in the fourth quarter worth about $825,000. Quadrature Capital Ltd bought a new stake in shares of DiaMedica Therapeutics during the 4th quarter worth about $188,000. Finally, Balyasny Asset Management L.P. acquired a new position in shares of DiaMedica Therapeutics during the 4th quarter valued at about $136,000. Institutional investors own 10.12% of the company’s stock.

DiaMedica Therapeutics Stock Down 0.9%

Shares of NASDAQ:DMAC opened at $7.71 on Wednesday. The firm has a fifty day moving average of $8.25 and a two-hundred day moving average of $7.50. DiaMedica Therapeutics has a 12-month low of $3.19 and a 12-month high of $10.42. The firm has a market capitalization of $401.54 million, a P/E ratio of -10.86 and a beta of 1.09.

About DiaMedica Therapeutics

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.